Author: Tracy Cooley
AP: Groups Claim Insurance Discrimination
In this August 18 article, Ricardo Alonso-Zaldivar highlights assertions by patient groups that new insurance …
Docs to FDA: Biosimilars should have different names than branded drugs
Yesterday, Fierce Biotech highlighted a letter written by more than 10 medical associations and 20 individual specialists …
New study shows hepatitis C burden may ease in future
Anew study published in the Annals of Internal Medicine projects that the prevalence of hepatitis …
NYT Columnist: Insurance Industry “Looking at the Costs of Sovaldi in the Wrong Way”
Margot Sanger-Katz’s article on a new drug that treats hepatitis C notes that despite the …
Treating Hepatitis C: Too Costly Not to Act
Today, The Hill published an op-ed – Treating hepatitis C: Too costly not to act …
BioCentury TV This Week: 340B Drug Discount Program Needs More Oversight
BIO’s Laurel Todd shared concerns that the 340B program has departed significantly from its original …
AIR 340B New Report: Contract Pharmacy Growth in 340B
Today, the Alliance for Integrity and Reform of 340B (AIR 340B) released a white paper …
Scientific American WorldView Super Session: The Future of Global Innovation
The sixth annual Scientific American WorldView super session packed the room late in the day …
NIH, Patients and Industry Ramp Up to AMP-lify Innovation
Speakers at Wednesday’s BIO 2014 Super Session – AMP-lifying Innovation: NIH, Patient Organizations & Leading …
Gates Foundation Issues Biotech Call to Action
Today, Trevor Mundel from the Bill & Melinda Gates Foundation discussed the untapped potential of …